Bioversys AG (BIOV) — Working Capital to Net Assets Ratio
Bioversys AG (BIOV) has a Working Capital to Net Assets ratio of 135.4% as of December 2025. Working capital of CHF80.97 Million (current assets of CHF89.87 Million minus current liabilities of CHF8.90 Million) is measured against net assets of CHF59.81 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See Bioversys AG net asset quality index to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Bioversys AG Working Capital to Net Assets (2024–2025)
This chart shows how Bioversys AG's Working Capital to Net Assets ratio has evolved across 2 annual periods from 2024 to 2025. As of December 2025, the ratio stands at 135.4%, reflecting working capital of CHF80.97 Million against net assets of CHF59.81 Million CHF. Check how tangible is Bioversys AG's equity to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Bioversys AG (2024–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Bioversys AG from 2024 to 2025, covering 2 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see BIOV market cap overview.
| Year | WC/NA Ratio | Working Capital (CHF) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 135.4% | CHF80.97 Million | CHF59.81 Million | CHF89.87 Million | CHF8.90 Million | ▼ -96.1 pp |
| 2024 | 231.5% | CHF24.73 Million | CHF10.68 Million | CHF34.40 Million | CHF9.67 Million | — |